A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

Trial Identifier: 6482-004
Sponsor: MSD
Start Date: May 2018
Primary Completion Date: March 2026
Study Completion Date: March 2026
Condition: Genetic Conditions; Kidney Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary – English

Trial Locations

Country Location
Denmark Aarhus, Denmark
France Paris, France
United Kingdom Cambridge, United Kingdom
United States, Maryland Bethesda, Maryland, United States, 20892
United States, Massachusetts Boston, Massachusetts, United States, 02114
United States, Michigan Ann Arbor, Michigan, United States, 48109
United States, Pennsylvania Philadelphia, Pennsylvania, United States, 19104
United States, Pennsylvania Pittsburgh, Pennsylvania, United States, 15232
United States, Tennessee Nashville, Tennessee, United States, 37232
United States, Texas Houston, Texas, United States, 77030
United States, Utah Salt Lake City, Utah, United States, 84112